---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024464"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:04:09.920637+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma reports Q3 net loss of $20.2M; LIFT-AD interim analysis supports continuation

## Summary
- Net loss of $20.2M ($0.53/shr) for Q3 2022 vs $15.7M ($0.42) in Q3 2021; cash $260.0M at Sep 30, 2022.
- R&D expenses $17.0M (up from $10.7M YoY) driven by clinical trial and personnel costs.
- LIFT-AD interim analysis supports continuation; DMC determined <150 more patients needed for adequate power on primary endpoint.
- Expects LIFT-AD enrollment completion mid-2023; topline data early 2024.
- ACT-AD Phase 2 data showed statistically significant improvement in NfL biomarker in patients not on background therapy.

## SEC filing metadata
- accession: 0000950170-22-024464
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017022024464/0000950170-22-024464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017022024464/atha-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024464
- JSON: https://secwatch.observer/filing/0000950170-22-024464.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024464.txt

## Key facts
- Earnings Releases
  LeonaBio, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the third quarter ended September 30, 2022 and reviewed recent clinical and corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000095017022024464/0000950170-22-024464-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.